Display options
Cite
Becker Y, Förster S, Gielen GH, et al. Paucimannosidic glycoepitopes inhibit tumorigenic processes in glioblastoma multiforme. Oncotarget. 2019;10(43):4449-4465doi: 10.18632/oncotarget.27056.
Becker, Y., Förster, S., Gielen, G. H., Loke, I., Thaysen-Andersen, M., Laurini, C., Wehrand, K., Pietsch, T., & Diestel, S. (2019). Paucimannosidic glycoepitopes inhibit tumorigenic processes in glioblastoma multiforme. Oncotarget, 10(43), 4449-4465. https://doi.org/10.18632/oncotarget.27056
Becker, Yvonne, et al. "Paucimannosidic glycoepitopes inhibit tumorigenic processes in glioblastoma multiforme." Oncotarget vol. 10,43 (2019): 4449-4465. doi: https://doi.org/10.18632/oncotarget.27056
Becker Y, Förster S, Gielen GH, Loke I, Thaysen-Andersen M, Laurini C, Wehrand K, Pietsch T, Diestel S. Paucimannosidic glycoepitopes inhibit tumorigenic processes in glioblastoma multiforme. Oncotarget. 2019 Jul 09;10(43):4449-4465. doi: 10.18632/oncotarget.27056. eCollection 2019 Jul 09. PMID: 31320997; PMCID: PMC6633888.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2019 Jul 09;10(43):4449-4465. doi: 10.18632/oncotarget.27056. eCollection 2019 Jul 09.

Paucimannosidic glycoepitopes inhibit tumorigenic processes in glioblastoma multiforme.

Oncotarget

Yvonne Becker, Sarah Förster, Gerrit H Gielen, Ian Loke, Morten Thaysen-Andersen, Christine Laurini, Kristin Wehrand, Torsten Pietsch, Simone Diestel

Affiliations

  1. Institute of Nutrition and Food Sciences, Department of Human Metabolomics, University of Bonn, Bonn 53115, Germany.
  2. Institute of Neuropathology, University of Bonn Medical Center, Bonn 53127, Germany.
  3. Department of Molecular Sciences, Macquarie University, Sydney, NSW 2109, Australia.

PMID: 31320997 PMCID: PMC6633888 DOI: 10.18632/oncotarget.27056

Abstract

Glioblastoma multiforme is an aggressive cancer type with poor patient outcomes. Interestingly, we reported previously a novel association between the little studied paucimannosidic

Keywords: AHNAK; N-glycosylation; cancer progression; glioblastoma multiforme; paucimannosidic epitopes

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare no potential conflict of interest.

References

  1. Clin Cancer Res. 2000 Jun;6(6):2562-72 - PubMed
  2. Anal Biochem. 1992 May 15;203(1):173-9 - PubMed
  3. N Engl J Med. 2005 Mar 10;352(10):987-96 - PubMed
  4. Nat Rev Cancer. 2005 Jul;5(7):526-42 - PubMed
  5. Brain. 2007 Oct;130(Pt 10):2596-606 - PubMed
  6. J Pathol. 2008 Dec;216(4):387-93 - PubMed
  7. Carbohydr Res. 2009 Aug 17;344(12):1391-6 - PubMed
  8. J Biomech. 2010 Jan 5;43(1):9-14 - PubMed
  9. J Cell Biol. 2010 Jan 11;188(1):11-9 - PubMed
  10. J Proteome Res. 2010 Mar 5;9(3):1533-40 - PubMed
  11. Amino Acids. 2011 Jul;41(2):271-90 - PubMed
  12. Mol Cell Proteomics. 2012 Sep;11(9):571-85 - PubMed
  13. J Biol Chem. 2012 Jul 13;287(29):24356-64 - PubMed
  14. Nat Protoc. 2012 Jun 07;7(7):1299-310 - PubMed
  15. Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):4009-14 - PubMed
  16. J Clin Oncol. 2013 Nov 10;31(32):4085-91 - PubMed
  17. Cancers (Basel). 2013 Aug 22;5(3):1103-19 - PubMed
  18. Int J Oncol. 2014 Feb;44(2):530-8 - PubMed
  19. J Proteome Res. 2014 Jan 3;13(1):277-88 - PubMed
  20. Oncogene. 2014 Sep 18;33(38):4675-84 - PubMed
  21. Science. 2014 Jun 20;344(6190):1396-401 - PubMed
  22. Cell Signal. 2014 Dec;26(12):2683-93 - PubMed
  23. Glycobiology. 2015 Jan;25(1):88-100 - PubMed
  24. Front Immunol. 2014 Aug 25;5:404 - PubMed
  25. J Biol Chem. 2015 Apr 3;290(14):8789-802 - PubMed
  26. Adv Cancer Res. 2015;126:305-44 - PubMed
  27. Glycobiology. 2015 Aug;25(8):869-80 - PubMed
  28. Nat Rev Cancer. 2015 Sep;15(9):540-55 - PubMed
  29. Melanoma Res. 2016 Apr;26(2):108-16 - PubMed
  30. Oncotarget. 2016 Jun 7;7(23):35478-89 - PubMed
  31. Mol Aspects Med. 2016 Oct;51:31-55 - PubMed
  32. J Hematol Oncol. 2016 Sep 29;9(1):100 - PubMed
  33. Glycoconj J. 2017 Apr;34(2):147-156 - PubMed
  34. Biomed Res Int. 2017;2017:8013575 - PubMed
  35. J Exp Clin Cancer Res. 2017 May 12;36(1):65 - PubMed
  36. Nat Commun. 2017 May 16;8:15237 - PubMed
  37. Mol Cell Proteomics. 2017 Aug;16(8):1507-1527 - PubMed
  38. J Cancer. 2017 Aug 25;8(15):2924-2932 - PubMed
  39. Mol Cancer Res. 2018 Aug;16(8):1287-1298 - PubMed
  40. Oncotarget. 2018 Sep 4;9(69):33077-33097 - PubMed
  41. Sci Rep. 2018 Sep 26;8(1):14379 - PubMed
  42. Front Oncol. 2018 Dec 07;8:565 - PubMed
  43. FEBS Lett. 2019 Apr;593(7):719-731 - PubMed
  44. Anal Biochem. 1995 Jan 1;224(1):75-82 - PubMed

Publication Types